CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
flotufolastat (18F) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06604442
NCT06604442Phase 4Completed
CompareCT.gov

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Blue Earth Diagnostics·interventional·Posted Sep 19, 2024·Updated May 12, 2026

In Brief

A Phase 4 clinical trial evaluating flotufolastat (18F) and piflufolastat (18F) for Prostate Cancer. Completed, enrolled 62 participants across 9 sites.

Detailed Summary

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsAixial Group

Timeline

Phase 4CompletedFinished
20252026
First PostedSep 19, 2024
Enrollment StartDec 4, 2024
Primary CompletionAug 29, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.8 years ago

Interventions

flotufolastat (18F)drug

Positron emission tomography (PET)

piflufolastat (18F)drug

Positron emission tomography (PET)